|
|
||||||||
a Department of Pathology, University of Virginia, Charlottesville, Virginia 22908
b Laboratory of Cellular and Developmental Biology, NIDDK, National Institutes of Health, Bethesda, Maryland 20892
In this study, we have mapped and characterized a B cell epitope of sulfated glycoprotein ZP2 (ZP2) as a step toward the development of a multi-epitope zona pellucida (ZP) vaccine. Recombinant polypeptides expressed by random deoxyribonuclease-digested fragments of ZP2 cDNA were screened for binding to IE-3, a monoclonal antibody to murine ZP2. Positive clones contained cDNA inserts encoding polypeptide corresponding to ZP2103134. When normal or ovariectomized female mice were immunized with three overlapping peptides that span this region of ZP2 (101120, 111130, 121140), only ZP2121140 elicited IgG antibodies that reacted with mouse ovarian ZP, indicative of the presence of native B epitope and helper T cell epitope in ZP2121140. To more finely map the ZP2 B cell epitope, a random peptide display library was screened with the IE-3 antibody, and a consensus tetramer sequence VxYK that matched the ZP2123126 sequence VRYK was located. Competitive immunofluorescence analysis with single alanine-substituted VxYK peptides ranked the relative contribution of the three critical B cell epitope residues as Y > V > K. A chimeric peptide was constructed that contained the YRYK motif of ZP2 and a bovine RNase T cell epitope. Although (C57BL/6xA/J) F1 (B6AF1) female mice immunized with the chimeric peptide developed ZP antibody response, this peptide elicited antibody only in mice of the histocompatibility complex (MHC) H-2k or b haplotype. In contrast, ZP2121140 peptide elicited antibody in inbred mice with three additional mouse MHC haplotypes. Moreover, although ZP2121140 contained a T cell epitope, no oophoritis was observed after immunization of B6AF1 mice with ZP2121140 in complete Freund's adjuvant (CFA). In a preliminary trial, female B6AF1 mice immunized with ZP2121140 in CFA had reduced litter sizes as compared with mice injected with CFA alone.
2 Correspondence: Kenneth S.K. Tung, Departments of Pathology, University of Virginia, Old Medical School, 4th Floor, Room 4888, Charlottesville, VA 22908. FAX: 804 924 8060; kst7k{at}virginia.edu
This article has been cited by other articles:
![]() |
J. A Eade, I. D Roberston, and C. M James Contraceptive potential of porcine and feline zona pellucida A, B and C subunits in domestic cats Reproduction, June 1, 2009; 137(6): 913 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Duckworth, K. Wilson, X. Cui, F. C Molinia, and P. E Cowan Immunogenicity and contraceptive potential of three infertility-relevant zona pellucida 2 epitopes in the marsupial brushtail possum (Trichosurus vulpecula) Reproduction, January 1, 2007; 133(1): 177 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hasegawa, N. Kanazawa, H. Sawai, S. Komori, and K. Koyama Pig zona pellucida 2 (pZP2) protein does not participate in zona pellucida formation in transgenic mice. Reproduction, September 1, 2006; 132(3): 455 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Naz, S. K. Gupta, J. C. Gupta, H. K. Vyas, and a. G.P. Talwar Recent advances in contraceptive vaccine development: a mini-review Hum. Reprod., December 1, 2005; 20(12): 3271 - 3283. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M Hardy, G. Clydesdale, and K. J Mobbs Development of mouse-specific contraceptive vaccines: infertility in mice immunized with peptide and polyepitope antigens Reproduction, October 1, 2004; 128(4): 395 - 407. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.-L. Xiang, F. Zhou, Y. Yang, and J.-P. Peng Construction of the Plasmid pCMV4-rZPC' DNA Vaccine and Analysis of Its Contraceptive Potential1 Biol Reprod, May 1, 2003; 68(5): 1518 - 1524. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Lou, K.-K. Park, S. Agersborg, P. Alard, and K. S. K. Tung Retargeting T Cell-Mediated Inflammation: A New Perspective on Autoantibody Action J. Immunol., May 15, 2000; 164(10): 5251 - 5257. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |